Epipen and Pancytopenia - a phase IV clinical study of FDA data

Summary:

Pancytopenia is reported as a side effect among people who take Epipen (epinephrine), especially for people who are male, 50-59 old, also take Zantac, and have Itching.

The phase IV clinical study analyzes which people have Pancytopenia when taking Epipen. It is created by eHealthMe based on reports of 23,690 people who have side effects when taking Epipen from the FDA, and is updated regularly.

What is Epipen?

Epipen has active ingredients of epinephrine. It is often used in anaphylaxis. eHealthMe is studying from 23,760 Epipen users. Check the latest studies of Epipen.

What is Pancytopenia?

Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets) is found to be associated with 1,792 drugs and 2,431 conditions by eHealthMe. Check the latest studies of Pancytopenia.

On Jul, 28, 2026

23,690 people reported to have side effects when taking Epipen.
Among them, 13 people (0.05%) have Pancytopenia.

Among these 13 people:

What is the gender of people who have Pancytopenia when taking Epipen? *

female: 46.15 %
male: 53.85 %

What is the age of people who have Pancytopenia when taking Epipen? *

What are other drugs people take besides Epipen? *

What are other side effects people have besides Pancytopenia? *

Nausea And Vomiting: 6 people, 46.15%
Zinc Deficiency: 4 people, 30.77%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 4 people, 30.77%
Type 1 Diabetes: 4 people, 30.77%
Hospitalisation: 4 people, 30.77%
Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 4 people, 30.77%
Haematemesis (vomiting of blood): 4 people, 30.77%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 4 people, 30.77%
Gastric Varices: 4 people, 30.77%
Anaemia (lack of blood): 4 people, 30.77%

What are the existing conditions these people have? *

Itching: 5 people, 38.46%
Viral Skin Infection: 4 people, 30.77%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 4 people, 30.77%
Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 4 people, 30.77%
Viral Infection: 4 people, 30.77%
Autoimmune Hepatitis: 4 people, 30.77%
Rickets (softening of bones): 4 people, 30.77%
Sleep Disorder: 4 people, 30.77%
Thrombocytopenia (decrease of platelets in blood): 4 people, 30.77%
Urticaria (rash of round, red welts on the skin that itch intensely): 4 people, 30.77%

* Approximation only. Some reports may have incomplete information.

Do you take Epipen and have Pancytopenia?

- Check whether Pancytopenia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Epipen:

Epipen (23,760 reports)

Pancytopenia treatments and more:

Pancytopenia (69,290 reports)

Browse all side effects of Epipen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pancytopenia:

Pancytopenia (1,792 drugs)

Browse all the conditions that are associated with Pancytopenia:

Pancytopenia (2,431 conditions)

Related publications that referenced our studies

Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on epinephrine (the active ingredients of Epipen) and Epipen (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.